



Guest Editors

Marcus A. Mall

Marcus A. Mall is Professor of Paediatrics and director of the Dept of Translational Pulmonology at the Heidelberg University Medical School, and head of the Division of Paediatric Pulmonology and Allergy and the Cystic Fibrosis Center at the Dept of Paediatrics, University Hospital Heidelberg, Heidelberg, Germany. In 2011, he was appointed director of the Translational Lung Research Center Heidelberg (TLRC) and member of the board of directors of the German Center for Lung Research (DZL). He is an active member of several professional societies, including the European Cystic Fibrosis Society (ECFS), the European Respiratory Society (ERS) and the American Thoracic Society (ATS). He serves on journal editorial boards and on the scientific committee of the ECFS.



Marcus Mall qualified in medicine at the University of Freiburg, Freiburg, Germany, and received his clinical training at the Universities of Freiburg and Heidelberg, and his postdoctoral training at the University of North Carolina at Chapel Hill, NC, USA, where he was appointed Assistant Professor of Medicine. In 2005, he received a grant from the European Commission to establish a Marie Curie Excellence Team at the University of Heidelberg, and in 2009 he was awarded the prestigious Heisenberg Professorship by the German Research Foundation. He is board certified in paediatrics, paediatric pulmonology and infectious diseases.

Marcus Mall's research is focused on the cellular and molecular pathogenesis of CF and other airway diseases, and the development of novel diagnostic approaches and therapeutic strategies. His research programme has been funded by the German Research Foundation (DFG), the German Ministry for Education and Research (BMBF), the European Commission, and others, and he has received several research awards. He developed a mouse that overexpresses the epithelial sodium channel (β ENaC), the first animal model with CF-like lung disease. He coordinates interdisciplinary translational research projects, integrating basic research with cohort studies and early phase clinical trials, to improve our understanding of CF lung disease and the translation of research results into the clinic.



J. Stuart Elborn

J. Stuart Elborn is Dean of the School of Medicine, Dentistry and Biomedical Sciences (SMDBS), Queen's University Belfast, Belfast, UK. He was previously director of the Centre for Infection and Immunity in SMDBS and Professor of Respiratory Medicine. He is a consultant physician in Belfast City Hospital (Belfast, UK), where he started an adult CF programme that now has 300 patients, and he collaborates closely with his paediatric colleagues who provide care for 180 patients. Additionally, he is president of the ECFS and is a trustee of the UK CF Trust.

Stuart Elborn has led a number of clinical trials involving antibiotics, anti-inflammatory agents and cystic fibrosis transmembrane conductance regulator (CFTR)-modulating drugs. He also leads a clinical trials programme in bronchiectasis. His team of pulmonary researchers has recently been selected as part of a Translational Research Partnership in the UK, which focuses on academics working with the pharmaceutical industry in pre-clinical and early clinical trials. His group is also part of the ECFS Clinical Trials Network. He is principal investigator on a number of early stage anti-inflammatory and potentially disease-modifying therapies in CF and other lung diseases.

Stuart Elborn has a major clinical and laboratory research programme in airways infection, funded jointly by the National Institutes of Health (Bethesda, MD, USA), the Research and Development Office in Northern Ireland, the UK Medical Research Council, the Science Foundation Ireland and the European Union Framework 7, investigating the clinical implications of bacterial diversity and, in particular, anaerobes in the CF airway. This involves clinical research and also a range of projects investigating the interaction between bacteria and the host innate immunity.